1. Emerging Targeted Therapies for Early Breast Cancer.
- Author
-
Schlam, Ilana, Tarantino, Paolo, Morganti, Stefania, Lynce, Filipa, Trapani, Dario, Mayer, Erica L., Garrido-Castro, Ana C., Waks, Ada, and Tolaney, Sara M.
- Subjects
THERAPEUTIC use of monoclonal antibodies ,THERAPEUTIC use of antineoplastic agents ,DRUG approval ,IMMUNE checkpoint inhibitors ,EPIDERMAL growth factor receptors ,BRCA genes ,EARLY detection of cancer ,METASTASIS ,CANCER relapse ,CELL receptors ,TREATMENT effectiveness ,TRANSFERASES ,COMBINED modality therapy ,BREAST tumors - Abstract
Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in the United States (US). Most patients are diagnosed with early-stage disease; however, there is still a need to prevent recurrences that often present as incurable metastatic disease. The treatment landscape of early-stage breast cancer is evolving rapidly. The immune checkpoint inhibitor pembrolizumab is approved in combination with neoadjuvant chemotherapy for the treatment of high-risk triple-negative breast cancer (TNBC). The cyclin-dependent kinase (CDK) 4 and 6 inhibitor abemaciclib is approved for adjuvant treatment of patients with high-risk hormone receptor (HR)-positive disease. While adjuvant olaparib has shown significant improvement in outcomes for patients with pathogenic/likely pathogenic BRCA1/2 mutations and high-risk human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and is approved in this setting. For the HER2-positive subtype, the post-neoadjuvant therapy can be tailored based on the response to neoadjuvant chemotherapy and HER2-targeted agents. In this narrative review, we summarize the most recent approvals for early-stage breast cancer as well as frequently encountered clinical challenges utilizing these medications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF